Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: An original Pt(iv) pro-drug based on Cisplatin and Tranilast

Daniele Lo Re; Diego Montagner; Dina Tolan; Claudio Di Sanza; Mar Iglesias; Alexandre Calon; E. Giralt

doi:10.1039/c8cc02071j

Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: An original Pt(iv) pro-drug based on Cisplatin and Tranilast

Daniele Lo Re, Diego Montagner, Dina Tolan, Claudio Di Sanza, Mar Iglesias, Alexandre Calon, E. Giralt

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.

Original language	English
Pages (from-to)	8324-8327
Number of pages	4
Journal	Chemical Communications
Volume	54
Issue number	60
DOIs	https://doi.org/10.1039/c8cc02071j
State	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c8cc02071j

Cite this

@article{0efa77efaeed42e08ca4a4ed678ceca5,

title = "Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: An original Pt(iv) pro-drug based on Cisplatin and Tranilast",

abstract = "Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.",

author = "\{Lo Re\}, Daniele and Diego Montagner and Dina Tolan and \{Di Sanza\}, Claudio and Mar Iglesias and Alexandre Calon and E. Giralt",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",

year = "2018",

doi = "10.1039/c8cc02071j",

language = "English",

volume = "54",

pages = "8324--8327",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "Royal Society of Chemistry",

number = "60",

}

TY - JOUR

T1 - Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin

T2 - An original Pt(iv) pro-drug based on Cisplatin and Tranilast

AU - Lo Re, Daniele

AU - Montagner, Diego

AU - Tolan, Dina

AU - Di Sanza, Claudio

AU - Iglesias, Mar

AU - Calon, Alexandre

AU - Giralt, E.

PY - 2018

Y1 - 2018

N2 - Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.

AB - Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85050735167&partnerID=8YFLogxK

U2 - 10.1039/c8cc02071j

DO - 10.1039/c8cc02071j

M3 - Article

C2 - 29796549

AN - SCOPUS:85050735167

SN - 1359-7345

VL - 54

SP - 8324

EP - 8327

JO - Chemical Communications

JF - Chemical Communications

IS - 60

ER -

Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: An original Pt(iv) pro-drug based on Cisplatin and Tranilast

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this